- Home
- GORO vs RFL Comparison
GORO vs RFL Comparison
Compare GORO & RFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GORO
- RFL
- Stock Information
- Founded
- GORO 1998
- RFL 2017
- Country
- GORO United States
- RFL United States
- Employees
- GORO N/A
- RFL N/A
- Industry
- GORO Precious Metals
- RFL Real Estate
- Sector
- GORO Basic Materials
- RFL Finance
- Exchange
- GORO Nasdaq
- RFL Nasdaq
- Market Cap
- GORO 40.2M
- RFL 48.4M
- IPO Year
- GORO N/A
- RFL N/A
- Fundamental
- Price
- GORO $0.41
- RFL $1.83
- Analyst Decision
- GORO Strong Buy
- RFL
- Analyst Count
- GORO 1
- RFL 0
- Target Price
- GORO $1.75
- RFL N/A
- AVG Volume (30 Days)
- GORO 521.6K
- RFL 68.5K
- Earning Date
- GORO 10-31-2024
- RFL 12-12-2024
- Dividend Yield
- GORO N/A
- RFL N/A
- EPS Growth
- GORO N/A
- RFL N/A
- EPS
- GORO N/A
- RFL N/A
- Revenue
- GORO $81,177,000.00
- RFL $540,000.00
- Revenue This Year
- GORO N/A
- RFL N/A
- Revenue Next Year
- GORO $48.90
- RFL N/A
- P/E Ratio
- GORO N/A
- RFL N/A
- Revenue Growth
- GORO N/A
- RFL 92.86
- 52 Week Low
- GORO $0.22
- RFL $1.29
- 52 Week High
- GORO $0.71
- RFL $2.50
- Technical
- Relative Strength Index (RSI)
- GORO 58.73
- RFL 43.35
- Support Level
- GORO $0.40
- RFL $1.86
- Resistance Level
- GORO $0.48
- RFL $2.50
- Average True Range (ATR)
- GORO 0.03
- RFL 0.12
- MACD
- GORO 0.01
- RFL -0.05
- Stochastic Oscillator
- GORO 53.13
- RFL 4.30
About GORO Gold Resource Corporation
Gold Resource Corp is a gold and silver producer, developer, and explorer with operations in Oaxaca, Mexico, and Nevada, USA. It targets low capital expenditure projects with the potential for generating high returns on capital. The company's two pipeline projects are; Don David Gold at Oaxaca, Mexico, and Back Forty at Michigan, United States of America.
About RFL Rafael Holdings Inc. Class B
Rafael Holdings Inc, through its subsidiaries, is a clinical stage, oncology-focused pharmaceutical company committed to the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. The company is a significant investor in two clinical stage oncology companies, Cornerstone Pharmaceuticals, Inc., and LipoMedix Pharmaceuticals Ltd.